OverviewChartNews
Derivatives
TraderScreen

FibroGen/  US31572Q8087  /

IEX
2024-04-22  9:59:19 PM Chg. -0.02 Volume Bid- Ask- High Low
1.13USD -1.74% 24,650
Turnover: 27,677.43		 -Bid Size: - -Ask Size: - 1.17 1.09
GlobeNewswire 04-02 FibroGen Announces Topline Results from Phase 1 Monotherapy Study of FG-3246 in Patients with Metast...
GlobeNewswire 03-26 FibroGen to Present at 23rd Annual Needham Virtual Healthcare Conference
GlobeNewswire 03-11 FibroGen Appoints Deyaa Adib, M.D. as Chief Medical Officer
GlobeNewswire 02-26 FibroGen Reports Fourth Quarter and Full Year 2023 Financial Results
GlobeNewswire 02-26 FibroGen Regains All Rights to Roxadustat from AstraZeneca in the United States and Other AstraZenec...
GlobeNewswire 02-20 FibroGen to Report Fourth Quarter and Full Year 2023 Financial Results
GlobeNewswire 02-05 FibroGen To Host Part I of Virtual KOL Investor Event Series to Review Pamrevlumab Clinical Program ...
GlobeNewswire 01-25 FibroGen Announces Completion of the Pamrevlumab Arm in Precision Promise, Pancreatic Cancer Action ...
GlobeNewswire 2023-12-09 FibroGen Presents Data from Phase 3 MATTERHORN Trial of Roxadustat in Patients with Anemia of Lower ...
GlobeNewswire 2023-12-08 FibroGen/Astellas’ EVRENZO (roxadustat) Making In-Roads in European Market as In-Class Challenger, A...
GlobeNewswire 2023-11-30 Zealand Pharma appoints Enrique Conterno and Elaine Sullivan as board observers
GlobeNewswire 2023-11-06 FibroGen Reports Third Quarter 2023 Financial Results
GlobeNewswire 2023-10-23 FibroGen to Report Third Quarter 2023 Financial Results
GlobeNewswire 2023-08-29 FibroGen Announces Topline Results from LELANTOS-2, a Phase 3 Clinical Study of Pamrevlumab in Ambul...
GlobeNewswire 2022-02-28 FibroGen Reports Fourth Quarter and Full Year 2021 Financial Results
GlobeNewswire 2022-02-14 FibroGen to Report Fourth Quarter and Full Year 2021 Financial Results
GlobeNewswire 2022-02-04 FibroGen to Present at SVB Leerink 11th Annual Global Healthcare Conference
GlobeNewswire 2022-01-04 FibroGen to Present at H.C. Wainwright Bioconnect Virtual Conference
GlobeNewswire 2021-12-20 FibroGen Exercises Exclusive License Option for HiFiBiO’s CCR8 Program
GlobeNewswire 2021-11-15 EQT Private Equity and Goldman Sachs Asset Management Complete Acquisition of Parexel
GlobeNewswire 2021-11-09 FibroGen Reports Third Quarter 2021 Financial Results
GlobeNewswire 2021-11-02 FibroGen to Present at Upcoming Investor Conferences
GlobeNewswire 2021-10-26 FibroGen to Report Third Quarter 2021 Financial Results
GlobeNewswire 2021-10-25 FibroGen Announces Analyses from Roxadustat Global Phase 3 Program at American Society of Nephrology...
GlobeNewswire 2021-08-25 FibroGen Announces Positive Topline Results from Phase 2 Clinical Trial of Roxadustat for the Treatm...